Navigation Links
Kinex Pharmaceuticals' Chief Scientific Officer, Dr. David Hangauer, named the American Cancer Society's 2013 Honoree for its Cuisine for a Cure event
Date:4/12/2013

BUFFALO, N.Y., April 12, 2013 /PRNewswire/ -- Kinex Pharmaceuticals announced that Dr. David Hangauer , co-founder and Chief Scientific Officer of Kinex, has been named the American Cancer Society's 2013 Honoree of the year for its Cuisine for a Cure event. 

"I am honored to be the 2013 honoree for the American Cancer Society Cuisine for a Cure event.  I have devoted much of my career to discovering better drugs for treating cancer, two of which have recently advanced to clinical trials.  Through these efforts I am constantly humbled by the courage and strength of the cancer patients.  To be able to work on such an important medical need is a privilege," said Dr. David Hangauer .

"Kinex was initially founded upon a scientific platform to develop better drugs for treating cancer.  This is not solely a professional endeavor for us.  Importantly, our company is driven by a deep personal commitment as we have all been touched by both the devastation of cancer and the hope and extended life that new compounds can bring when fighting the disease.  Dave is the foundation of our efforts in Kinex.  Progress in treatment regimens will continue as extremely productive and engaged scientists like Dr. David Hangauer lead the charge in the fight against cancer," quoted Dr. Allen Barnett , President Emeritus of Kinex. 

Dr. Johnson Lau , CEO of Kinex, commented, "Both patients and Kinex are fortunate to have Dr. Hangauer dedicated to the field of cancer.  His expertise in drug discovery, coupled with tireless effort and commitment, has generated two very promising novel compounds for the treatment of various tumor types that Kinex and our drug development partners, Hanmi Pharmaceuticals, Xiangxue Pharmaceuticals, and PharmaEssentia are actively pursuing.  His focus on improving patient's lives through the discovery and development of new and better drugs is well reflected by the recognition of his achievements at the American Cancer Society 2013 event.  Kinex is proud to have Dave as our cofounder and Chief Scientific Officer."

Kinex Inquiries:

Patrick Gallagher
Vice President, Business Development and Investor Relations
Kinex Pharmaceuticals
701 Ellicott Street
Buffalo, NY 14203
pgallagher@kinexpharma.com


'/>"/>
SOURCE Kinex Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory
2. Kinex Pharmaceuticals Receives Substantial Strategic Investment
3. Kinex Pharmaceuticals Appoints Mr. Patrick Gallagher Vice President of Business Development and Investor Relations
4. Hanmi and Kinex Announced Korean FDA Allowance of the KX01 IND Application
5. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
6. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
7. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
8. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
9. Icahn Issues Statement Regarding Amylin Pharmaceuticals
10. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... -- KEY FINDINGS North America ... in 2016 and is expected to continue in the ... large number of surgical procedures that are taking place ... the patient temperature management market.) Patient warming and cooling ... blood during surgeries, lowering the risks of neurological disorders ...
(Date:12/8/2016)... Dec. 8, 2016  Eli Lilly and Company (NYSE: ... its phase 3 EXPEDITION3 trial at the 9 th ... previously disclosed, solanezumab did not meet the primary endpoint ... initiated in people with mild dementia due to Alzheimer,s ... for solanezumab for the treatment of mild dementia due ...
(Date:12/8/2016)... 8 de dezembro de 2016  A Mederi Therapeutics Inc . anunciou ... tratamento não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto ... ... Live Stretta procedure performed and broadcast during the ... Wuhan Union Hospital ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia ... 1, 2017. The name change aligns the entire company with its existing ... care quality. , “We are very proud of the achievements associated with the ...
(Date:12/8/2016)... Pennsylvania (PRWEB) , ... December 08, 2016 , ... ... Duck Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which ... , “This was our first franchise-wide Quack Gives Back initiative, ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced the ... and Eric Hoessel to vice president of sales. , Litsinger joined Mirixa ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont ... and attorneys from the firm’s global Life Sciences & Medical Technology Group have been ...
(Date:12/8/2016)... ... 08, 2016 , ... Launching of the ... Instance Manager architecture, meeting the needs of multichannel growth and doubling the ... auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, administrative flexibility ...
Breaking Medicine News(10 mins):